» Authors » Olivia C Finney

Olivia C Finney

Explore the profile of Olivia C Finney including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 18
Citations 816
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Borgers J, Lenkala D, Kohler V, Jackson E, Linssen M, Hymson S, et al.
Nat Med . 2025 Jan; PMID: 39753970
New treatment approaches are warranted for patients with advanced melanoma refractory to immune checkpoint blockade (ICB) or BRAF-targeted therapy. We designed BNT221, a personalized, neoantigen-specific autologous T cell product derived...
2.
Gardner R, Ceppi F, Rivers J, Annesley C, Summers C, Taraseviciute A, et al.
Blood . 2019 Nov; 134(24):2149-2158. PMID: 31697826
Immunotherapy with the adoptive transfer of T cells redirected with CD19-specific chimeric antigen receptors (CARs) for B-lineage acute lymphoblastic leukemia (ALL) can salvage >80% of patients having relapsed/refractory disease. The...
3.
Healy S, Murphy S, Hume J, Shelton L, Kuntz S, Van Voorhis W, et al.
Clin Infect Dis . 2019 Oct; 71(6):1481-1490. PMID: 31621832
Background: Chemoprophylaxis vaccination with sporozoites (CVac) with chloroquine induces protection against a homologous Plasmodium falciparum sporozoite (PfSPZ) challenge, but whether blood-stage parasite exposure is required for protection remains unclear. Chloroquine...
4.
Gust J, Finney O, Li D, Brakke H, Hicks R, Futrell R, et al.
Ann Neurol . 2019 May; 86(1):42-54. PMID: 31074527
Objective: To test whether systemic cytokine release is associated with central nervous system inflammatory responses and glial injury in immune effector cell-associated neurotoxicity syndrome (ICANS) after chimeric antigen receptor (CAR)-T...
5.
Finney O, Brakke H, Rawlings-Rhea S, Hicks R, Doolittle D, Lopez M, et al.
J Clin Invest . 2019 Mar; 129(5):2123-2132. PMID: 30860496
Background: Chimeric antigen receptor (CAR) T cells can induce remission in highly refractory leukemia and lymphoma subjects, yet the parameters for achieving sustained relapse-free survival are not fully delineated. Methods:...
6.
Kunkele A, Brown C, Beebe A, Mgebroff S, Johnson A, Taraseviciute A, et al.
Biol Blood Marrow Transplant . 2018 Oct; 25(2):223-232. PMID: 30315942
Cytotoxic chemotherapy and radiation can render lymphocyte repertoires qualitatively and quantitatively defective. Thus, heavily treated patients are often poor candidates for the manufacture of autologous chimeric antigen receptor (CAR)-T cell...
7.
Talley A, Healy S, Finney O, Murphy S, Kublin J, Salas C, et al.
PLoS One . 2014 Nov; 9(11):e109654. PMID: 25405724
Background: Controlled human malaria infection (CHMI) studies which recapitulate mosquito-borne infection are a critical tool to identify protective vaccine and drug candidates for advancement to field trials. In partnership with...
8.
Finney O, Danziger S, Molina D, Vignali M, Takagi A, Ji M, et al.
Mol Cell Proteomics . 2014 Jul; 13(10):2646-60. PMID: 25023128
Malaria remains one of the most prevalent and lethal human infectious diseases worldwide. A comprehensive characterization of antibody responses to blood stage malaria is essential to support the development of...
9.
Finney O, Keitany G, Smithers H, Kaushansky A, Kappe S, Wang R
Vaccine . 2014 Mar; 32(19):2135-8. PMID: 24582635
Whole-parasite malaria vaccines have shown promise in clinical trials. We recently reported the first human trial of a malaria vaccine based on Plasmodium falciparum genetically attenuated parasites (PfGAP). Herein we...
10.
Spring M, Murphy J, Nielsen R, Dowler M, Bennett J, Zarling S, et al.
Vaccine . 2013 Sep; 31(43):4975-83. PMID: 24029408
Background: Immunization with genetically engineered, attenuated malaria parasites (GAP) that arrest during liver infection confers sterile protection in mouse malaria models. A first generation Plasmodium falciparum GAP (Pf p52(-)/p36(-) GAP)...